.jpg?format=webp&quality=80&width=3840)
A study investigated the role of YTHDF2, a protein that recognizes N6-methyladenosine (m6A) modified RNAs and accelerates their degradation in multiple myeloma (MM). The results showed that YTHDF2 is highly expressed in MM and is an independent prognostic factor for MM survival. Silencing YTHDF2 suppressed cell proliferation and caused cell cycle arrest, while overexpression of YTHDF2 promoted MM growth. The YTHDF2 accelerated the degradation of EGR1 mRNA in an m6A-dependent manner, and EGR1 acts as a tumor suppressor by inhibiting CDK2-cyclinE1 and activating p21cip1/waf1 transcription to suppress cell proliferation and cell cycle transition. These findings suggest that YTHDF2 could be a potential prognostic biomarker and therapeutic target for MM.
Like
Save
Share